Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Daicel and Novasep Link for Chromatography Services

July 9, 2007 | A version of this story appeared in Volume 85, Issue 28

Japan's Daicel Chemical Industries and Groupe Novasep of France will work together to provide pharmaceutical industry customers with large-scale chromatographic methods for producing chiral intermediates and active pharmaceutical ingredients. The venture will combine Daicel's capabilities, through its Chiral Technologies subsidiaries in Europe and the U.S., for developing chiral stationary phases and Novasep's expertise in computer simulation and optimization of chromatographic processes. A goal of the collaboration is to help streamline and promote the use of chromatography in the production of chiral compounds by demonstrating time- and cost-effective manufacturing approaches. Jean Blehaut, head of Novasep's pharma business unit, notes that drugs such as Pfizer's Zoloft, UCB's Keppra, and Cephalon's Nuvigil are already made with chromatographic technologies. Production processes will come with a guaranteed performance level and include all applicable licenses to Novasep and Daicel intellectual property.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.